Actavis selling brands to win FTC nod for Warner buy; Roche's Kadcyla beat rivals at holding off HER2+ breast cancer;

breast cancer

@FiercePharma: Trending on our website (still): If pharma reps can't get in doctors' front doors, try alternate routes. Story | Follow @FiercePharma

@EricPFierce: U.K. tosses lean, but important bone to pharma with expected extension of cancer drug fund. ICYMI Friday | Follow @EricPFierce

@CarlyHFierce: Bristol-Myers melanoma drug Yervoy helps patients live years longer, study finds. Story | Follow @CarlyHFierce

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

> Actavis ($ACT) agreed to sell off three oral contraceptives and an osteoporosis treatment to win Federal Trade Commission (FTC) approval for its $8.5 billion Warner Chilcott ($WCRX) buyout. Report

> Roche's ($RHHBY) new breast cancer treatment Kadcyla beat its older drug Herceptin and GlaxoSmithKline's ($GSK) Tykerb at holding off cancer growth in patients with HER2-positive disease. Report

> GlaxoSmithKline agreed to sell its thrombosis drugs and a related factory to Aspen Pharmacare for £700 million, or about $1.3 billion. Report

> Belgium's UCB won FDA approval for its anti-inflammatory drug Cimzia as a treatment for adults with psoriatic arthritis. Report

> An official Japanese panel found that Novartis ($NVS) may have violated domestic law on drug promotions with ads for its blood-pressure drug Diovan that cited flawed research. Report

> The FDA warned that Pfizer's ($PFE) high-powered antibacterial drug Tygacil increases the risk of death and said the company would add a "black box" warning to the drug's label. Report

> Hungarian watchdogs approved France-based Servier's offer to buy the shares of the drugmaker Egis that it doesn't already own. Report

Medical Device News

@FierceMedDev: Device tax at center of government funding battle. Article | Follow @FierceMedDev

@MarkHFierce: KKR made it official, grabbing an 80% stake of Panasonic's healthcare arm for $1.67B - much higher than predicted. ICYMI Friday | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Medtronic lands U.S. approval of early-generation artificial pancreas. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Intersect plugs positive drug-eluting sinus implant data. Item

> Life Tech to peddle Advanced Cell Diagnostics' RNA biomarker tech around the world. More

> KCI absorbs two acquisitions into wound care mega-company. Article

Biotech News

@FierceBiotech: AstraZeneca CEO celebrates 1st anniversary with promising lung cancer data. More | Follow @FierceBiotech

@JohnCFierce: Pfizer nabs autoimmune disease drug rights for $25M upfront. News | Follow @JohnCFierce

@DamianFierce: Few are optimistic about a last-minute budget deal. Here's what happens at the FDA after a shutdown: Article | Follow @DamianFierce

> Lundbeck to cull 200 staffers in cost-cutting drive. Item

> Relypsa pitches $126M IPO as lead CKD drug nears moment of PhIII truth. Story

> Achillion shares crushed in a rout as hep C blockbuster hopes fade. Article

> Roche's new round of lung cancer data keeps spotlight on immunotherapies. More

CRO News

> Quintiles jumps into personalized medicine for cancer trials. More

> Merged at last, PRA and RPS say they're fourth-largest CRO. Report

> InVentiv launches doc network for late-stage trials. Story

> JSS snaps up Latin American CRO. Article

> Parexel launches China-focused service as local demand heats up. News

Biotech IT News

> FDA taking hands-off approach to regulation of most apps. More

> Genohub talks up 'Kayak' for NGS services. Report

> NIH calls for comments on draft genomics data sharing policy. Story

> Business behind Google Earth for the human body raises $4M. Item

> Pfizer to give patients access to their trial data. Article

And Finally... Increased government healthcare spending led to better numbers on cancer survival in the EU, a study found. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.